Mark O’Sullivan is Head of BDO’s R&D Tax Credits and Incentives group in Ireland. He is one of the foremost experts in this space, having worked in R&D Tax Credit and Grant incentives since 2011.
Mark works with large multinationals, PLCs, and indigenous Irish businesses from all of Ireland’s growth focused sectors including, Pharma, MedTech, and Technology.
Mark has extensive experience in supporting clients through all aspects of R&D funding incentives and has a wealth of experience in successfully guiding companies through Revenue R&D Tax Credit enquiries / audits.
Mark is a member of Engineers Ireland and has professional qualifications in Medical Physics, Mechanical Engineering, Manufacturing & Design Engineering, Computing, as well as being ITI CTA qualified.
Global New Product Development portfolio lead for Medtronic’s Coronary & Hypertension business.
New Product Development lead for Medtronic Ireland’s Leadership team.
Chair of the Irish Medtech Association RDI Working Group
Co-lead for Medtronic Ireland’s Global Inclusion, Diversity and Engagement Initiative from 2021-2022, and currently executive sponsor for Medtronic Ireland’s Pride and STEM Employee Resource Groups
Vice-chair of IBEC’s Medtech and Engineering Leadership Development Taskforce 2021 & 2022.
Led Medtronic’s Global Inclusion, Diversity and Engagement Initiative for the Coronary and Structural Heart business Division from 2018- 2019.
Ronan has worked in Medtronic for 20 years in New Product Development across a range of Cardiovascular areas, including Coronary, Hypertension, Cardiac Rhythm and Heart Failure, Peripheral Vascular and Structural Heart products.
Ronan spent 6 years at NUI, Galway, where he completed a degree in Mechanical Engineering and a Masters in Engineering Science.
John has worked in IDA for 22 years, joining IDA from its sister agency Enterprise Ireland in 2002. His IDA career started in in IDA’s Engineering Division. From 2006 to 2009 he completed a successful overseas assignment in IDA’s Silicon Valley Office. On his return from Silicon Valley John worked as part of IDA’s Clean Technologies Division. In 2011 John took over as Regional Manager for the North West Region and managed the expanded Border Region (North East and North West) for the period 2015 to 2019. John joined the Medical Technologies Department in February 2021 as East Coast Manager before assuming his current role in October 2023.
John studied Chemistry at Queens University Belfast graduating with an honours degree in 1992. Following that he joined Enterprise Ireland in 1992 initially working as an industrial / analytical chemist providing a range of services to Irish based industry, laterally working in a business advisory role with Enterprise Ireland in the North West region based in Sligo. While working John has returned to study a number of times completing a Masters Degree in Environmental Protection in 1999 from IT Sligo, a Diploma in Business Strategy from the Irish Management Institute in 2003 and a Masters Degree in Management from UCD Smurfit Business School in 2017.
Dr Elizabeth (Liz) McGloughlin is the co-founder of start-up Tympany Medical, a med-tech company based in Galway, which develops endoscopes for the ENT market, specifically sinus surgery. Her team has developed Solascope, an endoscope designed to enable panoramic visualisation via a rotation portion to the tip – an innovative mechanism for use in complex rhinology cases. Solascope is at the cutting edge of surgical imaging and technology, and aims to assist surgeons in addressing the growing number of minimally invasive surgeries-commencing with Sinus Surgery.
Solascope brings various technical areas together to enable less-invasive surgical techniques and deliver improves outcomes for both the patient and hospital system. With experience in medicine, anaesthesia, and critical care, she has a deep understanding of the clinical needs and challenges in the ENT field, and how to translate them into innovative solutions.
Liz completed her Master of Science in BioInnovation at NUI Galway and gained valuable insights and connections from working with the Mayo Clinic team as part of the BioInnovate Fellowship. Liz and the team have built a significant funding record, patent portfolio and product pipeline for Tympany medical, with team members in disciplines including Optical Physics, Biomedical Engineering and Miniaturised Electronics. Liz has led the team to secure over €8m in non-dilutive funding and over €6m in investment to date.
Dr Sadhana Trivedi is Global Medical Director MedSurg Solventum. She is a Plastic & Reconstructive Surgeon and holds 15 years of clinical experience in Ireland & India. In her current role, she is responsible for new product introduction, post-market clinical follow-up, clinical trial designs and regulatory submissions.
Dr Trivedi has worked with Bristol Myers Squibb for pre-launch preparation and launch of innovative medications. While working with Allianz Care, she led the Medical Affairs department of Allianz Care and delivered global value-based healthcare including the development of medical strategy, clinical services, medical education programs, and settlement of medical claims.
Dr Trivedi is passionate about the future of healthcare and the potential of data and technology to transform the quality of healthcare and improve outcomes.
Dr Trivedi has a keen interest in education and delivers lectures at the University College of Dublin, Ireland, and Griffith College Dublin, Ireland on medical innovations and transformation in healthcare. She is also a board member of the Irish Medtech Association, Chair of Medtech Connect, Vice chair of Research Development and Innovation working group of Irish Medtech in Ireland.
Selio Medical is a startup medical device company, based in Dublin, specialised in the development, manufacture and commercialisation of novel biomaterials and devices to meet large unmet clinical needs. Selio is a spin out from Bio-Innovate, UCC and TCD.
Selio has developed a patent protected, platform technology, to pre-seal percutaneous needle access thereby preventing dangerous complications associated with these common interventional procedures.
The first indication is the reduction of lung biopsy associated pneumothorax. Unfortunately, one in three lung biopsy patients suffer from a pneumothorax and the Selio Pre-B Seal System is designed to provide protection against this common, costly and dangerous complication.
Selio Medical is now working on the next exciting indication for our platform technology.
Dr Stafford has had a 25+ year career at the interface of research, innovation and enterprise development across multiple sectors such as agrifood, health, lifesciences and technology in Ireland, US and UK. He was appointed as the Head of Knowledge Transfer Ireland (KTI) and Head of Stakeholder Engagement for Research & Innovation Division in Enterprise Ireland at the end of February 2024. Prior to this, he was a Senior Development Advisor and Digital Health Sector lead in the Technology & Services Division in EI. Christian returned to EI in 2021, having been the General Manager of the INFANT Maternal & Child Health Research Centre from 2016. Previous to this role, he worked for Enterprise Ireland’s Research & Innovation Division in commercialisation of research and industrial-academic collaboration in lifesciences and food sectors.
Show more
Finbar Dolan is cofounder and CEO of Versono Medical. Finbar has over 20 years of executive and leadership experience within the Medical Device Industry and has worked with CR Bard, Medtronic, GTI, Lake Region/Integer, Arc Devices, in product development, strategic R&D and manufacturing operations. Finbar has also contributed on a pro bono basis to initiatives in IBEC’s MedTech Ireland, the IRDG, the American Chamber of Commerce Ireland and Engineers Ireland. A chartered engineer, Finbar holds PhD, MBA and BSc degrees and is a BioInnovate fellow.
Show more
Chris Murphy is the CEO and co-founder of Bluedrop Medical. Bluedrop Medical are a medical technology company based in Galway. They have developed an AI enabled remote patient monitoring technology targeted at the early intervention and prevention of diabetic foot ulcers.
Diabetic foot ulcers are one of the leading cost-drivers of diabetes and lead to approximately 100,000 amputations in the US each year. Bluedrop Medical’s OneStep foot scanner is used by the patient in their home, in a 30 second scan images and temperature data of the feet are captured. This data is sent to the cloud for analysis by Bluedrop using proprietary software technology.
Bluedrop Medical have raised over €15M in funding from investors ranging from VC funds, the European Union, and angel investors. In 2023 Bluedrop Medical completed all FDA/HIPAA compliance activities and now has a number of active pilots and trials in the USA.